Media stories about Abbott Laboratories (NYSE:ABT) have been trending somewhat positive this week, Alpha One Sentiment reports. The research group, a subsidiary of Accern, identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Alpha One ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Abbott Laboratories earned a news impact score of 0.13 on Alpha One’s scale. Alpha One also assigned media coverage about the healthcare product maker an impact score of 80 out of 100, indicating that recent news coverage is likely to have an impact on the stock’s share price in the near future.
Here are some of the headlines that may have effected Alpha One’s analysis:
A number of research analysts recently issued reports on the stock. Jefferies Group LLC reiterated a “buy” rating and issued a $51.00 price target on shares of Abbott Laboratories in a research note on Friday. Cowen and Company restated an “outperform” rating and set a $48.00 price objective on shares of Abbott Laboratories in a research report on Saturday, April 22nd. Barclays PLC boosted their price objective on shares of Abbott Laboratories from $50.00 to $52.00 and gave the stock an “overweight” rating in a research report on Thursday, April 20th. Morgan Stanley restated an “equal weight” rating and set a $42.00 price objective on shares of Abbott Laboratories in a research report on Wednesday, April 19th. Finally, TheStreet upgraded shares of Abbott Laboratories from a “c+” rating to a “b” rating in a research report on Wednesday, March 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and twelve have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $48.73.
Shares of Abbott Laboratories (NYSE:ABT) opened at 43.86 on Friday. Abbott Laboratories has a 12 month low of $36.76 and a 12 month high of $45.84. The firm’s 50 day moving average is $44.04 and its 200 day moving average is $41.89. The stock has a market capitalization of $76.11 billion, a price-to-earnings ratio of 45.64 and a beta of 0.97.
Abbott Laboratories (NYSE:ABT) last released its earnings results on Wednesday, April 19th. The healthcare product maker reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.05. The firm had revenue of $6.34 billion for the quarter, compared to analyst estimates of $6.16 billion. Abbott Laboratories had a return on equity of 15.74% and a net margin of 6.71%. Abbott Laboratories’s revenue was up 29.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.41 earnings per share. On average, equities analysts predict that Abbott Laboratories will post $2.47 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Monday, May 15th. Investors of record on Friday, April 14th will be issued a dividend of $0.265 per share. This represents a $1.06 dividend on an annualized basis and a yield of 2.42%. The ex-dividend date is Tuesday, April 11th. Abbott Laboratories’s payout ratio is currently 113.98%.
In related news, VP Robert E. Funck sold 25,500 shares of the stock in a transaction on Thursday, February 23rd. The stock was sold at an average price of $45.50, for a total value of $1,160,250.00. Following the completion of the transaction, the vice president now owns 117,579 shares in the company, valued at approximately $5,349,844.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Roger Bird sold 5,600 shares of the stock in a transaction on Thursday, April 27th. The shares were sold at an average price of $43.82, for a total value of $245,392.00. Following the completion of the transaction, the insider now owns 51,313 shares of the company’s stock, valued at approximately $2,248,535.66. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 52,692 shares of company stock worth $2,374,632. 0.26% of the stock is owned by corporate insiders.
About Abbott Laboratories
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.